Depression as a predictor of postoperative functional performance status (PFPS) and treatment adherence in head and neck cancer patients: a prospective study

Journal of Otolaryngology-Head & Neck Surgery

Hadi Seikaly¹  Vincent Biron¹  David Côté¹  Daniel O’Connell¹  Jeffrey Harris¹  Nicholas Mitchell²  Margaret Nesbitt¹  Jace Dergousoff²  Brittany Barber¹ 

[1] Division of Otolaryngology-Head & Neck Surgery, University of Alberta Hospital, 1E4, Walter Mackenzie Centre, 8440-112 St, Edmonton T6G 2B7, AB, Canada;Department of Psychiatry, University of Alberta Hospital, 1E1, Walter Mackenzie Centre, 8440-112 St, Edmonton T6G 2B7, AB, Canada

关键词: Postoperative functional performance;    Head neck cancer;    Depression;   

Others  :  1226221
DOI  :  10.1186/s40463-015-0092-4

 received in 2015-06-03, accepted in 2015-09-02,  发布年份 2015

【 摘 要 】

Background

Head and neck cancer (HNC) is a debilitating disease due in part to its effects on function, including speech, swallowing, and cosmesis. Previous studies regarding depression in HNC have focused on demographic predictors, incidence, and quality of life studies. There is, however, a paucity of studies that objectively address depressive symptoms in HNC patients and the resultant effects on post-treatment functional performance status. The aim of this study was to assess the relationship between preoperative depressive symptoms (PDS) and postoperative functional performance status (PFPS), in addition to other predictors of rehabilitation and survival.

Methods

A prospective cohort study was undertaken at the University of Alberta, including all new adult HNC patients undergoing surgery as primary therapy for HNC from May 2013 to January 2014. Baseline depressive symptoms were measured on the Quick Inventory of Depressive Symptoms (QIDS) questionnaire 2 weeks preoperatively and PFPS was assessed 12 months postoperatively on the Functional Assessment of Cancer Therapy-Head & Neck (FACT-HN) scale. Secondary outcomes included completion of adjuvant therapy, narcotic dependence, return to detrimental habits, loss of follow-up, and length of hospital stay (LOHS). Differences between the Normal-Mild and Moderate-Severe QIDS groups were assessed using Mann–Whitney and Fischer Exact statistical analyses.

Results

Seventy-one patients were included in the study. Mild and Moderate-Severe PDS were 35.2 % and 18.3 %, respectively. Significantly lower FACT-HN scores were noted in the Moderate-Severe group at 12 months (p = 0.03). The risk ratio (RR) for FACT-HN score < 50 % at 12 months in the Moderate-Severe group was 5.66. In addition, significantly lower completion of adjuvant treatment (p = 0.03), significantly higher incidence of narcotic dependence (p = 0.004), and significantly higher LOHS (24 days vs. 18 days; p = 0.02) was observed in the Moderate-Severe group. There was no significant difference in loss of follow-up between the 2 groups (p = 0.64).

Conclusions

The incidence and severity of PDS in HNC patients treated with surgery is high (53.5 %). Patients with Moderate-Severe PDS have significantly decreased PFPS, increased narcotic use, decreased completion of adjuvant therapy, and a longer LOHS. HNC patients should be monitored closely for depressive symptoms.

【 授权许可】

   
2015 Barber et al.

【 图 表 】

Fig. 1.

【 参考文献 】

• [1]Sehlen S, Lenk M, Herschback P, Aydemir U, Dellian M, Schymura B et al.. Depressive symptoms after radiotherapy for head and neck cancer. Head Neck. 2003; 25:1004-18.
• [2]Misono S, Weiss NS, Fann JR, Redman M, Yueh B. Incidence of suicide in persons with cancer. J Clin Oncol. 2008; 26(29):4731-8.
• [3]Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan PT, Kornstein S, Manber R, Thase ME, Kocsis JH, Keller MB. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDSSR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003; 54:573-83.
• [4]Trivedi MH, Rush AJ, Ibrahim HM, Carmody TJ, Biggs MM, Suppes T, Crismon ML, Shores-Wilson K, Toprac MG, Dennehy EB, Witte B, Kashner TM. The inventory of depressive symptomatology, clinician rating (IDS-C) and self-report (IDS-SR), and the quick inventory of depressive symptomatology, clinician rating (QIDS-C) and self-report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med. 2004; 34:73-82.
• [5]List MA, D’Antonio LL, Cella DF, Siston A, Mumby P, Haraf D, Vokes E. The performance status scale for head and neck cancer patients and the Functional Assessment of Cancer Therapy-Head & Neck (FACT-H&N) scale: a study of utility and validity. Cancer. 1996; 77:2294-301.
• [6]Movsas B, Scott C, Watkins-Bruner D. Pretreatment factors significantly influence quality of life in cancer patients: a Radiation Therapy Oncology (RTOG) analysis. Int J Radiat Oncol Biol Phys. 2006; 65(3):830-5.
• [7]Coyne JC, Pajak TF, Harris J, Konski A, Movsas B, Ang K et al.. Emotional well-being does not predict survival in head and neck cancer patients: a Radiation Therapy Oncology Group study. Cancer. 2007; 110(11):2569-75.
• [8]Yount S, List M, Du H, Yost K, Bode R, Brockstein B et al.. A randomized study comparing embedded versus enacted FACT – Head and Neck Symptom Index (FHNSI) scores. Qual Life Res. 2007; 16(10):1615-26.
• [9]Arrieta O, Angulo L, Nunez-Valencia C, Dorantes-Gallereta Y, Macedo E, Martinez-Lopez D, Alvarado S, Corona-Cruz J, Onate-Ocana F. Association of depression and anxiety on quality of life, treatment adherence, and prognosis in patients with advanced non-small cell lung cancer. Ann Surg Oncol. 2013; 20:1941-8.
• [10]Hu L, Ku F, Wang Y, Shen C, Hu Y, Yeh C, et al. Anxiety and depressive disorders among patients with esophageal cancer in Taiwan: a nationwide population-based study. Support Care Cancer 2015;23(3):733–40.
• [11]Lin B, Starmer H, Gourin C. The relationship between depressive symptoms, quality of life, and swallowing function in head and neck cancer patients 1 year after definitive therapy. Laryngoscope. 2012; 122:1518-25.
• [12]Urba S, Gatz J, Shen W, Hossain A, Winfree K, Koustenis A, Peterson P, Cohen EE. Quality of life scores as prognostic factors of overall survival in advanced head and neck cacner: analysis of a phase III randomized trial of pemetrexed plus cisplatin versus cisplatin monotherapy. Oral Concol. 2012; 48(8):723-9.
• [13]Shuman A, Terrell J, Light E, Wolf GT, Bradford CR, Chepeha D et al.. Predictors of pain among patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2012; 138(12):1147-54.
• [14]Moye J, June A, Martin LA, Gosian J, Herman L, Naik A. Pain is prevalent and persisting in cancer survivors: differential factors across age groups. J Geriatr Oncol. 2014; 5(2):190-6.
• [15]Berg CJ, Thomas AN, Mertens AC, Schauer GL, Pinsker EA, Ahluwalia JS, Khuri FR. Correlates of continued smoking versus cessation among survivors of smoking-related cancers. Psychooncology. 2013; 22(4):799-806.
• [16]Jerjes W, Upile T, Radhi H, Petrie A, Abiola J, Adams A et al.. The effect of tobacco and alcohol and their reduction/cessation on mortality in oral cancer patients: short communication. Head Neck Oncol. 2012; 4(6):1-5.
• [17]Lazure KE, Lydiatt WM, Denman D, Burke W. Association between depression and survival or disease recurrence in patients with head and neck cancer enrolled in a depression prevention trial. Head Neck. 2009; 31:888-92.
• [18]Peters LJ, Goepfert H, Ang KK, Byers RM, Maor MH, Guillamondegui O et al.. Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomized trial. Int J Radiat Oncol Biol Phys. 1993; 26(1):3-11.
• [19]Barton MB, Morgan G, Smee R, Tiver KW, Hamilton C, Gebski V. Does waiting time affect the outcome of larynx cancer treated by radiotherapy? Radiother Oncol. 1997; 44(2):137-41.
• [20]Le Q, Fu KK, Kroll S. Influence of fraction size, total dose, and overall time on local control of T1-T2 glottic carcinoma. Int J Radiat Oncol Biol Phys. 1997; 39(1):115-26.